[…]
Publication Type: Poster Presentation
A CD33-Deleted Allograft (Trem-cel) Enables Post-Hematopoietic Cell Transplant (HCT) Maintenance Dosing of Gemtuzumab Ozogamicin (GO) with Therapeutic Levels of Drug Exposure and Low Hematologic and Hepatic Toxicity in Patients with High-Risk Acute Myeloid Leukemia (AML)
Multimodal atlas of paired diagnosis and relapse AML reveals surface antigens for multi-specific immunotherapy
SITC – 2024 – POSTER PRESENTATION 1092
Leveraging CRISPR/Cas9 and HDR to create an engineered CD33 CAR-T to treat AML […]
Immuno-Oncology Summit – 2024 – Poster Presentation P26
Purification of CAR+ T Cells Reveals Impact of Untransduced Cells in CAR-T Drug Product […]
Read More… from Immuno-Oncology Summit – 2024 – Poster Presentation P26
Deploying a CD45-Antibody Drug Conjugate for Allogeneic Hematopoietic Stem Cell Transplant in Non-Human Primates
ASGCT – 2024 – Poster Presentation 1775
Gene-Edited Hematopoietic Stem Cells to Enable Next-Generation CAR-T Cell Therapy for the Treatment of AML […]
KEYSTONE SYMPOSIA – 2024 – POSTER PRESENTATION 1040
Uncovering Molecular and Functional Dynamics of Human Hematopoietic Stem Cells during In Vitro Culture for Cell Therapy Manufacturing […]
Read More… from KEYSTONE SYMPOSIA – 2024 – POSTER PRESENTATION 1040
Tandem Meetings – 2024 – Encore Poster Presentation 310
Trem-cel, a CRISPR/Cas9 Gene-Edited Allograft Lacking CD33, Shows Rapid Primary Engraftment with CD33-Negative Hematopoiesis in Patients with High-Risk Acute Myeloid Leukemia (AML) and Avoids Hematopoietic Toxicity During Gemtuzumab Ozogamicin (GO) Maintenance Post-Hematopoietic Cell Transplant (HCT) […]
Read More… from Tandem Meetings – 2024 – Encore Poster Presentation 310